Celldex Therapeutics (CLDX) Operating Income (2016 - 2025)
Historic Operating Income for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$73.6 million.
- Celldex Therapeutics' Operating Income fell 4122.89% to -$73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.2 million, marking a year-over-year decrease of 3726.31%. This contributed to the annual value of -$195.1 million for FY2024, which is 2622.98% down from last year.
- As of Q3 2025, Celldex Therapeutics' Operating Income stood at -$73.6 million, which was down 4122.89% from -$63.9 million recorded in Q2 2025.
- Celldex Therapeutics' 5-year Operating Income high stood at -$13.4 million for Q2 2021, and its period low was -$73.6 million during Q3 2025.
- Over the past 5 years, Celldex Therapeutics' median Operating Income value was -$36.4 million (recorded in 2022), while the average stood at -$38.8 million.
- In the last 5 years, Celldex Therapeutics' Operating Income skyrocketed by 1792.1% in 2021 and then crashed by 17080.36% in 2022.
- Quarter analysis of 5 years shows Celldex Therapeutics' Operating Income stood at -$20.3 million in 2021, then plummeted by 37.09% to -$27.9 million in 2022, then tumbled by 70.8% to -$47.6 million in 2023, then fell by 17.64% to -$56.0 million in 2024, then plummeted by 31.4% to -$73.6 million in 2025.
- Its Operating Income was -$73.6 million in Q3 2025, compared to -$63.9 million in Q2 2025 and -$62.7 million in Q1 2025.